[EN] ISOQUINOLINE DERIVATIVES AS INHIBITORS OF BAX AND/OR BAK, COMPOSITIONS AND USES THEREOF [FR] DÉRIVÉS D'ISOQUINOLINE UTILISÉS EN TANT QU'INHIBITEURS DE BAX ET/OU DE BAK, COMPOSITIONS ET UTILISATIONS ASSOCIÉES
摘要:
The present application relates to isoquinoline compounds of Formula (I), to processes for their preparation and to compositions comprising them. More particularly, the present application relates to compound of Formula (I) that have activity as inhibitors of Bcl2- associated X protein (BAX) and/or Bcl-2 antagonist killer (BAK), and to their use in the treatment of diseases, disorders or conditions treatable by inhibiting BAX and/or BAK such as neurodegenerative diseases, disorders or conditions.
[EN] ISOQUINOLINE DERIVATIVES AS INHIBITORS OF BAX AND/OR BAK, COMPOSITIONS AND USES THEREOF [FR] DÉRIVÉS D'ISOQUINOLINE UTILISÉS EN TANT QU'INHIBITEURS DE BAX ET/OU DE BAK, COMPOSITIONS ET UTILISATIONS ASSOCIÉES
摘要:
The present application relates to isoquinoline compounds of Formula (I), to processes for their preparation and to compositions comprising them. More particularly, the present application relates to compound of Formula (I) that have activity as inhibitors of Bcl2- associated X protein (BAX) and/or Bcl-2 antagonist killer (BAK), and to their use in the treatment of diseases, disorders or conditions treatable by inhibiting BAX and/or BAK such as neurodegenerative diseases, disorders or conditions.
[EN] ISOQUINOLINE DERIVATIVES AS INHIBITORS OF BAX AND/OR BAK, COMPOSITIONS AND USES THEREOF<br/>[FR] DÉRIVÉS D'ISOQUINOLINE UTILISÉS EN TANT QU'INHIBITEURS DE BAX ET/OU DE BAK, COMPOSITIONS ET UTILISATIONS ASSOCIÉES
申请人:[en]SUNNYBROOK RESEARCH INSTITUTE
公开号:WO2023155019A1
公开(公告)日:2023-08-24
The present application relates to isoquinoline compounds of Formula (I), to processes for their preparation and to compositions comprising them. More particularly, the present application relates to compound of Formula (I) that have activity as inhibitors of Bcl2- associated X protein (BAX) and/or Bcl-2 antagonist killer (BAK), and to their use in the treatment of diseases, disorders or conditions treatable by inhibiting BAX and/or BAK such as neurodegenerative diseases, disorders or conditions.